ASCO Annual Meeting 2025

Explore BIOTYPE's products for precision oncology at the 2025 ASCO Annual Meeting in Chicago!

Our MODAPLEX platform offers comprehensive molecular profiling for endometrial cancer, enabling detection of POLE/POLD1 mutations (crucial for identifying the favorable ultramutated subtype), microsatellite instability (MSI), and copy number variations (CNV) in a single run, streamlining workflows and conserving valuable tissue. Simultaneously, MODAPLEX provides precise detection of actionable FGFR alterations in urothelial bladder cancer, identifying 13 key FGFR3 mutations and 12 clinically significant FGFR2/3 gene fusions, which is essential for guiding targeted treatment decisions.

Learn how MODAPLEX can revolutionize your lab's approach to biomarker detection and discuss its applications with Dr. Abhishek Aich.

Please contact Abhishek Aich, PhD via direct message on LinkedIn for a face-to-face discussion on the latest advances in bladder cancer diagnostics.

We look forward to talking to you!